Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to… Click to show full abstract
Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed.
Keywords:
myelofibrosis;
update allogeneic;
stem cell;
stem;
2024 update
Journal Title: American Journal of Hematology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: American Journal of Hematology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!